Intellia Therapeutics (NTLA) vs Achieve Life Sciences (QUIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Intellia Therapeutics is the larger company by market cap ($1.40 billion vs $573.2 million), about 2.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTLA | QUIT |
|---|---|---|
| Share price | $10.00 | $5.56 |
| Market cap | $1.40B | $573.25M |
| 1-day change | +5.04% | -5.28% |
| YTD return | +11.23% | — |
| 1-year return | +21.80% | — |
| 5-year return | -91.16% | — |
| EPS (TTM) | $-3.35 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $67.67M | — |
| Revenue growth (YoY) | +16.92% | — |
| Net income (latest FY) | $-412.69M | $-54.65M |
| Operating margin | -651.67% | — |
| Net margin | -609.85% | — |
| 52-week high | $18.48 | $8.64 |
| 52-week low | $8.09 | $2.62 |
| Distance from 52-week high | -45.89% | -35.65% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +127.80% | +162.23% |
| Average volume | 5.03M | 1.38M |
| Shares outstanding | 140.36M | 103.10M |
| Employees | 377 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Intellia Therapeutics is about 2.4 times larger than Achieve Life Sciences by market value ($1.40B vs $573.25M).
About Intellia Therapeutics
NTLA stock →Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 377 employees
About Achieve Life Sciences
QUIT stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees
NTLA vs QUIT FAQ
Which is bigger, Intellia Therapeutics or Achieve Life Sciences?
Intellia Therapeutics (NTLA) is larger, with a market capitalization of $1.40B compared with $573.25M for Achieve Life Sciences (QUIT).
Are Intellia Therapeutics and Achieve Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.